SEC Form 4 · accession 0000899243-16-015926
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Schembri
Officer — See Remarks
Period of report
Mar 10, 2016
Accepted (ET)
Mar 14, 2016 · 6:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.40 | Mar 10, 2016 | A | 7,500 | A | Mar 10, 2016 | Apr 8, 2025 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1On April 9, 2015, the reporting person was granted an option to purchase 30,000 shares of Common Stock under the issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 7,500 of the shares underlying such option.
Remarks
VP, Finance and Administration and Corporate Secretary